


PROGRAM



HFSA Virtual Board Certification Review 2020

*Advanced Heart Failure &
Transplant Cardiology*



Visit hfsa.org/boardreview2020 to learn more.



ABOUT THE COURSE

The HFSA Virtual Board Certification Review 2020 content is based on the ABIM content blueprint for the certification examination in Advanced Heart Failure and Transplant Cardiology. It will be held over the course of 3 days (July 24, July 31, August 1) and include pre-recorded ondemand webinars.

This activity will use concise didactic presentations by national experts, case studies, and panel discussions. An audience response system (ARS) will be utilized throughout all presentations and to deliver ABIM style questions in designated session time. Additional question and answer periods with faculty will enable attendees to drive the discussion of according to their most pressing clinical challenges. A reading list compiled for the activity contains additional references regarding guideline- and evidence- based therapy.

The following areas are addressed:

- Epidemiology and Causes of Heart Failure
- Pathophysiology of Heart Failure
- Evaluation of Heart Failure
- Management of Hospitalized Patients
- Management of Heart Failure
- Comorbidities or Coexisting Conditions
- Cardiac Surgery in Heart Failure
- Heart Transplant
- Mechanical Circulatory Support
- Pulmonary Arterial Hypertension
- Contemporary HF Management Topics

MEETING SUPPORTERS

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year's HFSA Virtual Board Certification Review Course:

Abbott
Amgen
AstraZeneca
Medtronic
Merck
Relypsa

ABIM CERTIFICATION DEADLINES

ABIM Certification Exam Date:

October 21, 2020

Registration Dates:

December 1, 2019 – June 15, 2020

Late Registration Dates:

June 16-28, 2020 (additional fees apply)

Visit www.abim.org for additional information about the certification exam.

PROGRAM COMPONENTS

The program will be made up of the following components to allow attendees greater access to the content.

PRE-RECORDED WEBINAR SERIES: HEART FAILURE FUNDAMENTALS

Available in early July, this pre-recorded, ondemand webinar series features the basics and can be completed at the attendee's convenience.

LIVESTREAM SESSIONS

Three, non-consecutive days of livestreamed sessions (July 24, July 31, August 1) delivered by top experts in the field. Attendees should anticipate being online throughout to receive maximum value from these live sessions. If a livestream session must be missed due to other circumstances, all livestream sessions will be available for attendees to download and access approximately two weeks after the meeting concludes. Full agenda is available at hfsa.org/boardreview2020/program

FACULTY "OFFICE HOURS"

Post-meeting, virtual livestream Q&A panel taking place in September to allow attendees to ask last-minute questions prior to the examination in October.

ADDITIONAL BONUS FEATURES

In addition to the core program components, attendees will have access to the following:

- A question bank
- Recommended reading list
- Live polling, Q&A, and chat features available during the livestream days
- Chat with fellow attendees and faculty throughout the course of the meeting





ABIM CERTIFICATION DEADLINES

This HFSA Virtual Board Certification Review 2020 has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

CREDIT DESIGNATION

This HFSA Virtual Board Certification Review has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

Physicians

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 19 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19 MOC points in the Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

LEARNING OBJECTIVES

Upon completion of the activity, participants will demonstrate improved competence and ability to:

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
2. Focus study efforts on filling identified knowledge gaps
3. Practice for the certification examination with ABIM-style multiple-choice test questions

For Clinical Practice:

1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Concise presentations by national experts will focus on blueprint content and will be augmented by board-review-type questions posed using an audience-response system.





FACULTY

CO-CHAIRS

Akshay S. Desai, MD, MPH, FHSA

Medical Director, Cardiomyopathy and Heart Failure Program,
Advanced Heart Disease Section
Brigham and Women's Hospital
Boston, MA

Jonathan Rich, MD, FHSA

Associate Professor of Medicine
Northwestern University, Feinberg School of Medicine
Medical Director, Mechanical Circulatory Support Program
Program Director, Advanced Heart Failure and Transplant Fellowship
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
Chicago, IL

Nancy Sweitzer, MD, PhD, FHSA

Professor of Medicine
Chief of Cardiology
Director, Sarver Heart Center
University of Arizona
Tucson, AZ

Meredith Brisco-Bacik, MD, MSCE

Associate Professor of Medicine
Director, Heart Failure Clinical Research
Advanced Heart Failure and Cardiac Transplantation
The Lewis Katz School of Medicine at Temple University
Philadelphia, PA

Daniel Burkhoff, MD, PhD

Columbia University
New York, NY

Jennifer Cowger, MD, MS

Medical Director of Mechanical Circulatory Support Program
Co-Director of the Cardiac Intensive Care Unit
Henry Ford Hospitals, Detroit Michigan
Associate Professor, Wayne State University
Detroit, MI

Akshay S. Desai, MD, MPH, FHSA

Medical Director, Cardiomyopathy and Heart Failure Program,
Advanced Heart Disease Section
Brigham and Women's Hospital
Boston, MA

Mark Drazner, MD, MSc, FHSA

Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor
University of Texas Southwestern Medical Center
Dallas, TX

James Fang, MD, FHSA

Professor of Medicine
Chief, Division of Cardiovascular Medicine
Executive Director, Cardiovascular Service Line
University of Utah
Salt Lake City, UT

Sadiya Khan, MD, MSc

Associate Professor of Medicine – Cardiology
Associate Professor of Preventive Medicine – Epidemiology
Northwestern University Feinberg School of Medicine
Chicago, IL

Michelle Kittleson, MD, PHD

Professor of Medicine
Director of Post Graduate Medical Education in Heart Failure
and Transplantation
Director of Heart Failure Research
Cedars Sinai Medical Center
Beverly Hills, CA

Liviu Klein, MD, MS

Associate Professor of Medicine
Division of Cardiology, University of California San Francisco
Director, Cardiology Clinical Research
Director, Mechanical Circulatory Support & Heart Failure
Device Program
University of California, San Francisco
San Francisco, CA

Eric Krieger, MD

Associate Professor of Medicine
Director, Seattle Adult Congenital Heart Service
Director, Adult Congenital Heart Disease Fellowship
Attending Physician, University of Washington Medical Center
University of Washington School of Medicine
Seattle Children's Hospital
Seattle, WA





FACULTY (CONTINUED)

Gregory Lewis, MD

Section Head, Heart Failure
 Director, Cardiopulmonary Exercise Testing Laboratory
 Medical Director, Cardiac Transplantation Program
 Massachusetts General Hospital
 Boston, MA

Jon Lomasney, MD

Associate Professor of Pathology
 Associate Professor of Pharmacology
 Feinberg School of Medicine of Northwestern University
 Chicago, IL

Anju Nohria, MD, MSc

Associate Physician, Brigham and Women's Hospital
 Assistant Professor of Medicine, Harvard Medical School
 Boston, MA

Sean Pinney, MD

Professor of Medicine
 Co-Director of the Heart & Vascular Center
 Director of Heart Failure & Transplantation and Director of
 Clinical & Translational Research
 Director, Advanced Heart Failure and Transplantation Pro-
 gram
 University of Chicago
 Chicago, IL

Jonathan Rich, MD, FHFSA

Associate Professor of Medicine
 Northwestern University, Feinberg School of Medicine
 Medical Director, Mechanical Circulatory Support Program
 Program Director, Advanced Heart Failure and Transplant
 Fellowship
 Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
 Chicago, IL

Joseph Rogers, MD

Chief Medical Officer
 Duke University Health System
 Professor of Medicine – Cardiology
 Duke University
 Durham, NC

Sanjiv Shah, MD

Stone Professor of Medicine
 Director of Research, Bluhm Cardiovascular Institute
 Director, Northwestern HFpEF Program
 Division of Cardiology, Department of Medicine
 Northwestern University Feinberg School of Medicine
 Chicago, IL

Nancy Sweitzer, MD, PhD, FHFSA

Professor of Medicine
 Chief of Cardiology
 Director, Sarver Heart Center
 University of Arizona
 Tucson, AZ

Jane Wilcox, MD, MSc, FHFSA

Assistant Professor of Medicine
 Director, Myocardial Recovery Program
 Associate Director, T1 Center for
 Cardiovascular Therapeutics
 Bluhm Cardiovascular Institute
 Chicago, IL

Clyde W. Yancy, MD, MSc, FHFSA

Vice-Dean, Diversity & Inclusion
 Chief of Cardiology
 Professor of Medicine
 Professor, Medical Social Sciences
 Associate Director
 Bluhm Cardiovascular Institute
 Deputy Editor, JAMA Cardiology
 Chicago, IL





FACULTY DISCLOSURES

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

Meredith Brisco-Bacik, MD, MSCE
 Mark Drazner, MD, MSc, FHFSA
 Sadiya Khan, MD, MSc
 Michelle Kittleson, MD, PHD
 Eric Krieger, MD
 Jon Lomasney, MD
 Joseph Rogers, MD
 Sanjiv Shah, MD

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

Daniel Burkhoff, MD, PhD – Research Grant: Abiomed (Education), Ancora Medical, Tenax, Fire 1; Ownership Interest: PV Loops LLC (non-relevant financial relationship); Consultant-Advisory Board: BackBeat Medical, CardioDyme, Janssen Pharmaceuticals, Medtronic, Axon Therapies; Corvia, PVLoops LLC

Jennifer Cowger, MD, MS – Research Grant: Abbott, Medtronic; Speaker-Honoraria: Abbott, Medtronic; Consultant-Advisory Board: Abbott, Medtronic

Akshay Desai, MD, MPH, FHFSA – Research Grant: Alnylam; AstraZeneca; Novartis; Consultant-Advisory Board: Abbott; Alnylam; AstraZeneca; Amgen; Biofourmis; Noston Scientific; Boehringer-Ingelheim; Corvidia; DalCor Pharma; Merck; Novartis; Relypsa; Regeneron

Liviu Klein, MD, MS – Consultant-Advisory Board: Boston Scientific (Steering Committee); Medtronic (Steering Committee)

Anju Nohria, MD, MSc – Research Grant: Amgen, Inc.; Consultant-Advisory Board: Takeda Oncology

Sean Pinney, MD – Speaker-Honoraria: CareDX; Consultant-Advisory Board: CareDx

Nancy Sweitzer, MD, PhD, FHFSA – Research Grant: Merck, Novartis; Consultant-Advisory Board: Myokardia

Jane Wilcox, MD, MSc, FHFSA – Speaker-Honoraria: Medtronic; Consultant-Advisory Board: Cytokinetics

Clyde Yancy, MD, MSc, FHFSA – Financial Disclosure: Spousal employment at Abbott, Inc.

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.





HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020

- Pre-Recorded Webinar Series: Heart Failure Fundamentals
- 2020 HFSA Board Certification Review Course – July 24, July 31-August 1, 2020
 - » Day 1 | July 24 | 3:00 PM – 6:00 PM ET
 - » Day 2 | July 31 | 11:00 AM - 6:00 PM ET
 - » Day 3 | August 1 | 11:00 AM – 5:45 PM ET
- Faculty “Office Hours” Virtual Live-Stream Panel – September 2020 (TBD)

PRE-RECORDED WEBINAR SERIES: HEART FAILURE FUNDAMENTALS

TALK TITLE			SPEAKER
		Heart Failure Epidemiology and Risk Factors	Sadiya Khan
		Pathophysiology I: Cellular and Energetic Considerations	Daniel Burkhoff
		Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations	Daniel Burkhoff
		Diagnosis and Clinical Assessment	Mark Drazner
		Device Therapy in Heart Failure	Liviu Klein
		Cardio-Oncology for the HF boards	Anju Nohria
		Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards	Jon Lomasney

VIRTUAL LIVE-STREAM MEETING: DAY 1

July 24, 2020 | 3 PM - 6 PM EST

ET Time	CT Time	PT Time	TALK TITLE	SPEAKER
3:00 PM	2:00 PM	12:00 PM	Welcome & HFSA Introduction	Akshay Desai; John Barnes
SESSION I - Cardiac Transplantation				Moderator: Akshay Desai
3:30 PM	2:30 PM	12:30 PM	Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies	Nancy Sweitzer
4:00 PM	3:00 PM	1:00 PM	Immunology: The Basics, PRA, Sensitization, Crossmatch	Sean Pinney
4:30 PM	3:30 PM	1:30 PM	Rejection: Cellular and Antibody Mediated	Sean Pinney
5:00 PM	4:00 PM	2:00 PM	Managing Immunosuppression and Drugs	Michelle Kittleson
5:30 PM	4:30 PM	2:30 PM	Heart Transplant, Clinical Outcomes and Complications	Michelle Kittleson
6:00 PM	5:00 PM	3:00 PM	Adjourns	





HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020 (CONTINUED)

VIRTUAL LIVE-STREAM MEETING: DAY 2

July 31, 2020 | 11 AM - 6 PM EST

ET Time	CT Time	PT Time	TALK TITLE	SPEAKER
11:00 AM	10:00 AM	8:00 AM	Welcome	Akshay Desai
SESSION II: Key Issues in HF Management				Moderator: Jonathan Rich
11:30 AM	10:30 AM	8:30 AM	Hemodynamics in HF I	James Fang
12:00 PM	11:00 AM	9:00 AM	Hemodynamics in HF II	James Fang
12:30 PM	11:30 AM	9:30 AM	Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)	Clyde Yancy
1:00 PM	12:00 PM	10:00 AM	Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)	Mark Drazner
1:30 PM	12:30 PM	10:30 AM	BREAK	
1:45 PM	12:45 PM	10:45 AM	HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)	Sanjiv Shah
2:15 PM	1:15 PM	11:15 AM	Management of the Hospitalized HF Patient	Meredith Brisco-Bacik
2:45 PM	1:45 PM	11:45 AM	Management of Common Arrhythmias in HF (including AF)	Liviu Klein
3:15 PM	2:15 PM	12:15 PM	Management of Comorbidities in Heart Failure	Meredith Brisco-Bacik
3:45 PM	2:45 PM	12:45 PM	BREAK	
SESSION III: Specific Heart Failure Syndromes				Moderator: Jonathan Rich
4:00 PM	3:00 PM	1:00 PM	Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)	Akshay Desai
4:30 PM	3:30 PM	1:30 PM	Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)	Jane Wilcox
5:00 PM	4:00 PM	2:00 PM	Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)	Sanjiv Shah
Q&A Panel I				
5:30 PM	4:30 PM	2:30 PM	Q&A ---- Overview	Chairs
6:00 PM	5:00 PM	3:00 PM	Adjourns	





HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020 (CONTINUED)

VIRTUAL LIVE-STREAM MEETING: DAY 3

August 1, 2020 | 11 AM - 5:45 PM EST

ET Time	CT Time	PT Time	TALK TITLE	SPEAKER
11:00 AM	10:00 AM	8:00 AM	Welcome & Q/A	Akshay Desai
SESSION IV - Shock/MCS				Moderator: Nancy Sweitzer
11:30 AM	10:30 AM	8:30 AM	Cardiogenic Shock Management	Nancy Sweitzer
12:00 PM	11:00 AM	9:00 AM	MCS I: Durable MCS Devices and Outcomes	Joseph Rogers
12:30 PM	11:30 AM	9:30 AM	MCS II: Temporary Support Devices and ECMO for the Boards	Jennifer Cowger
1:00 PM	12:00 PM	10:00 AM	MCS III: MCS Complications and Patient Management	Jennifer Cowger
1:30 PM	12:30 PM	10:30 AM	MCS IV: Troubleshooting (with HARVI)	Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer
2:30 PM	1:30 PM	11:30 AM	BREAK	
SESSION V: Special Topics in HF				Moderator: Akshay Desai
2:45 PM	1:45 PM	11:45 AM	Assessment of Functional Capacity including cardiopulmonary exercise testing	Gregory Lewis
3:15 PM	2:15 PM	12:15 PM	Adult Congenital Heart Disease for the HF Specialist	Eric Krieger
3:45 PM	2:45 PM	12:45 PM	Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)	Akshay Desai
4:15 PM	3:15 PM	1:15 PM	Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)	Jane Wilcox
4:45 PM	3:45 PM	1:45 PM	Pulmonary Hypertension	Jonathan Rich
Q&A Panel II				
5:15 PM	4:15 PM	2:15 PM	Q&A ---- Overview	Chairs
5:45 PM	4:45 PM	2:45 PM	Adjourns	

Faculty "Office Hours" Virtual Live-Stream Panel

September 4, 2020

ET Time	CT Time	PT Time	TALK TITLE	SPEAKER
TBD	TBD	TBD	Special Office Hour - Q&A	Akshay Desai, Nancy Sweitzer, Jonathan Rich





9211 Corporate Blvd, Suite 270
Rockville, MD 20850

T: (301) 798-4493 | F: (301) 798-7794 | www.hfsa.org

Visit hfsa.org/boardreview2020 to learn more.